UPB Upstream Bio, Inc. Common Stock

XNAS 10.40 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

UPB $10.40 —
Key stats
$10.40
52-Week Range
$2.70 – $33.68
YTD
-61.58%
IV Rank (30D)
6.31
Straddle Price
$14.60
P/C Vol Ratio
1.75
Market Cap
$0.2B
Open
$2.77
Day Range
$2.70 – $2.92
Volume
492,940
Prev Close
$2.80
Fair Value
+50.0% vs price

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.15%
Beta vs SPY1.29
Cost of Equity (CAPM)12.22% (VRP-adj)
WACC12.00%
Volatility Risk Premium+271.7pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+13.2%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-57.8%
Book / Price178.4% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-4321.2%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$5.49 (Market Anchor value)
SMA 20 / Bollinger Mid$4.27
Bollinger Width / SMA202064.3% (drives anchor stability)
Net Debt$-0.1B
Market Cap$0B
Peers used for multiples: ABEO, CLDX, DCTH (filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$6.49
Deviation
+50.0%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B $16.64 16% median 3.3× · 3 peers
Peer P/S $0.66 16% median 10.3× · 3 peers
Market Anchor (SMA50) $5.49 69% stability 85% (BB-width)
Options Expected (B-L 30d) $3.18 0% 5 strikes · skew -1.31
As of 2026-10-22 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.2B
Employees
75
List Date
2024-10-11
CIK
0002022626
Next Earnings
2026-11-04 (After-Close)
EPS Forecast
($0.67) (5 est.)
Headquarters
Waltham, MA
Homepage
https://www.upstreambio.com

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, …

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'24'25'26Avg
Jan---33.93%14.81%-9.56%
Feb---20.14%-74.35%-47.24%
Mar---17.96%16.88%-0.54%
Apr--38.21%-1.40%18.41%
May--2.56%-11.06%-4.25%
Jun--3.00%-14.36%-5.68%
Jul--41.89%-12.60%14.64%
Aug--10.23%3.12%6.68%
Sep---7.16%-19.54%-13.35%
Oct12.73%38.75%-42.86%*2.87%
Nov-11.67%14.31%--1.32%
Dec-23.99%-6.31%---15.15%
Total-24.31%36.37%-89.29%-25.74%
* Only 3 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $4.15
SMA 50: $5.41
SMA 200: $10.09
Current: $2.88
EMA 12: $3.45
EMA 26: $4.22
MACD: -0.7697 | Signal: -0.1068
BEARISH
ADX (14): 53.55
STRONG TREND
+DI: 5.70
−DI: 38.62

Momentum Oscillators

RSI (14): 18.77
OVERSOLD
Stoch %K: 4.40
Stoch %D: 2.99
Williams %R: -92.29

Volume & Volatility

BB Upper: $6.08
BB Lower: $2.23
NEUTRAL
OBV: -27,544,243
Vol SMA 20: 1,162,941
Vol ROC: -82.81%
ATR: $0.34
True Range: $0.22
HV 20: 100.2%
HV 30: 86.0%
HV 60: 78.2%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary Overall assessment: NEUTRAL (6/10) Key drivers: Positive news sentiment, trend support from SMAs Primary risks: High volatility, potential breakdown below $8.18 2-3 sentence investment thesis: UPB is poised for a rebound due to positive clinical trial news and trend support, but remains susceptible to high volatility. Recent news sentiment impact: Positive headlines have contributed to the recent price action.

Technical Analysis Trend Direction: Short-term (1-4 weeks): Ranging Medium-term (1-3 months): Uptrend Long-term (3-12 months): Bullish

Support/Resistance Levels: Key levels to monitor: $8.18 (lower Bollinger Band), $9.76 (upper Bollinger Band)

Momentum Signals: RSI interpretation: Neutral (39.72) - not overbought or oversold MACD signal: Bearish (-0.36 / Signal: -0.04) Bollinger Bands position: Neutral

Volume Analysis: Volume trends: Mixed signals from OBV and volume rate of change Institutional interest signals: High IV premium indicates market is pricing in potential move

News & Sentiment Analysis Recent Headlines Summary: Positive news headlines on chronic obstructive pulmonary disease clinical trials and severe asthma therapeutics have driven recent price action.

Sentiment Assessment: Aggregate news sentiment: POSITIVE (4/5)

Catalyst Identification: Upcoming events: Earnings announcements, investor conferences

Market Narrative: News has aligned with technical signals, supporting the current uptrend. However, high volatility remains a concern.

Risk & Volatility Assessment Beta Interpretation: High risk relative to market (beta 1.37 > SPY)

Volatility Regime: Current vs historical volatility levels: High (0.92) - stock moves more than market

Options Market Signals: IV rank: Low (22.3%) indicating historically low volatility Put/call ratios: Bullish sentiment (104 calls vs 6 puts) Unusual activity: None

Downside Protection: Support levels: $8.18, $7.80 (lower Bollinger Band)

Market Context & Positioning Sector Performance: Relative strength vs sector/market: Above average

Institutional Activity: Volume patterns suggesting institutional interest: High IV premium and put/call ratios

Correlation Analysis: How stock moves relative to market (R-squared interpretation): 0.18 - low correlation, indicating independent price action

Relative Valuation: Position within trading range: Mid-range ($8.37)

Key Levels & Action Items Critical Price Levels: Support/resistance to monitor: $8.18, $9.76 (upper Bollinger Band)

Breakout/Breakdown Levels: Technical levels that could trigger significant moves: $7.80 (lower Bollinger Band), $10.00

Time-Sensitive Catalysts: Earnings announcements, investor conferences

Risk Management: Stop-loss levels and position sizing considerations: Monitor volume and IV premiums to adjust risk exposure.

Note: This report is a comprehensive analysis based on the provided data. The assessment is neutral due to mixed signals from technical indicators and news sentiment.

Generated
News
All UPB news →
Showing 1–10 of 11
Page 1 of 2
Earnings History
5 of 5 under expected move
Avg Expected Move
29.90%
Avg Actual Move
3.71%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2025-08-06 After-Close 30.50% 5.26% 0.17x Within
2025-11-05 After-Close 21.38% 1.29% 0.06x Within
2026-03-25 After-Close 19.80% 3.38% 0.17x Within
2026-05-13 After-Close 22.44% 6.09% 0.27x Within
2026-08-12 Pre-Market 55.36% 2.54% 0.05x Within

Earnings calendar: this week’s reports with expected vs actual moves →

UPB Options Activity & IV Rank

UPB IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 92.6%
7-DTE IV: —
Expected Move: $14.60
7-DTE Move: $14.60
Days to Exp: 29 (2026-11-20)

Options Flow

Call Volume: 120
Put Volume: 210
P/C Volume: 1.75
BEARISH
Call OI: 245
Put OI: 270
P/C OI: 1.102
Total OI: 515

ATM Options Pricing

ATM Call: $7.50
ATM Put: $7.10
Call %: 72.1%
Put %: 68.3%

Chain Summary

Chain Volume: 374
Chain OI: 691
Last Updated: 10/22/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 49th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
49%
vs own history
GEX tilt
+0.49
OI-weighted, today
Vanna tilt
+0.31
δ-sensitivity to IV
Charm tilt
-0.84
δ-decay vs time
Vanna tilt +0.31: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.84: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 3 ATM contracts, 0k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
ATM 109.0% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)6.3LowOct 22
Straddle Price (30 DTE)$14.60Oct 22
Beta Analysis

Risk Metrics

Beta: 1.2199
Alpha: -174.39%
Correlation: 0.1731
R-Squared: 3.0%
Stock Volatility: 89.7%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own UPB
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$7.9M
0.01%
#1757 of 3716+22.0%13F
Point72 Hedge fund
Steve Cohen
$3.1M
0.00%
#1139 of 1945+154.3%13F
Renaissance Technologies Hedge fund
Jim Simons
$909K
0.00%
#2351 of 3138+111.4%13F
Rockefeller Capital Management Family office
Rockefeller family
$5K
0.00%
#4237 of 47290.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

UPB Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 54,230,678 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

150 filers52,902,714 shares$413.47M value97.55% of float
# Filer Shares Value % of Total % of Float Period
1 Vanguard Group Inc Custodian 2,388,439 $64.85M 15.68% 4.40% 2025-12-31
2 FMR LLC Custodian 8,162,897 $56.49M 13.66% 15.05% 2026-06-30
3 ORBIMED ADVISORS LLC 5,693,589 $39.40M 9.53% 10.50% 2026-06-30
4 Norges Bank 3,768,619 $26.08M 6.31% 6.95% 2026-06-30
5 BlackRock, Inc. Custodian 3,753,358 $25.97M 6.28% 6.92% 2026-06-30
6 Decheng Capital LLC 2,724,868 $18.86M 4.56% 5.02% 2026-06-30
7 Enavate Sciences GP, LLC 2,459,703 $17.02M 4.12% 4.54% 2026-06-30
8 Vanguard Capital Management LLC 1,876,734 $12.99M 3.14% 3.46% 2026-06-30
9 Millennium Management LLC Custodian 1,143,775 $7.91M 1.91% 2.11% 2026-06-30
10 D. E. Shaw & Co., Inc. Custodian 1,036,044 $7.17M 1.73% 1.91% 2026-06-30
11 JPMorgan Chase & Co Custodian 1,012,044 $7.01M 1.70% 1.87% 2026-06-30
12 Qube Research & Technologies Ltd 978,500 $6.77M 1.64% 1.80% 2026-06-30
13 Parkman Healthcare Partners LLC 935,247 $6.47M 1.57% 1.72% 2026-06-30
14 Geode Capital Management, LLC Custodian 931,261 $6.45M 1.56% 1.72% 2026-06-30
15 SEB Asset Management AB 878,473 $6.08M 1.47% 1.62% 2026-06-30
16 Woodline Partners LP 831,481 $5.75M 1.39% 1.53% 2026-06-30
17 State Street Corp 766,323 $5.30M 1.28% 1.41% 2026-06-30
18 Vanguard Portfolio Management LLC 712,667 $4.93M 1.19% 1.31% 2026-06-30
19 Bain Capital Life Sciences Investors, LLC 600,949 $4.16M 1.01% 1.11% 2026-06-30
20 AQR Capital Management, LLC Custodian 544,869 $3.77M 0.91% 1.00% 2026-06-30
21 Morgan Stanley Custodian 524,632 $3.63M 0.88% 0.97% 2026-06-30
22 BNP Paribas Financial Markets Custodian 511,546 $3.54M 0.86% 0.94% 2026-06-30
23 Walleye Capital LLC 498,490 $3.45M 0.83% 0.92% 2026-06-30
24 Y-Intercept (Hong Kong) Ltd 642,574 $3.39M 0.82% 1.18% 2026-09-30
25 Trexquant Investment LP 466,430 $3.23M 0.78% 0.86% 2026-06-30
3 filers$256.04K notional
# Filer Notional Value % of Total Period
1 Citadel Advisors LLC Custodian $103.80K 40.54% 2026-06-30
2 Jane Street Group, LLC Custodian $82.35K 32.16% 2026-06-30
3 Susquehanna International Group, LLP Custodian $69.89K 27.30% 2026-06-30
# Filer Notional Value % of Total Period

UPB Insider Trading (Form 4)

Latest: 2026-09-17
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-17 Everett Rand Sutherland Chief Executive Officer Sell (S) −2,095 $5.49 -$11.5K EDGAR
2026-09-17 Aaron Deykin Chief Medical Officer Sell (S) −895 $5.49 -$4.9K EDGAR
2026-09-17 Adam Houghton Chief Business Officer Sell (S) −700 $5.49 -$3.8K EDGAR
2026-09-17 Allison Ambrose General Counsel Sell (S) −485 $5.49 -$2.7K EDGAR
2026-09-17 Michael Gray CFO and COO Sell (S) −853 $5.49 -$4.7K EDGAR
2026-06-17 Michael Gray CFO and COO Sell (S) −853 $6.10 -$5.2K EDGAR
2026-06-17 Aaron Deykin Chief Medical Officer Sell (S) −895 $6.10 -$5.5K EDGAR
2026-06-17 Everett Rand Sutherland Chief Executive Officer Sell (S) −2,095 $6.10 -$12.8K EDGAR
2026-06-17 Adam Houghton Chief Business Officer Sell (S) −700 $6.10 -$4.3K EDGAR
2026-06-17 Allison Ambrose General Counsel Sell (S) −477 $6.10 -$2.9K EDGAR
2026-06-11 Marcella K. Ruddy Director Grant (A) +17,096 opt — EDGAR
2026-06-11 Harold Edward Fleming Director Grant (A) +17,096 opt — EDGAR
2026-06-11 Ronald C Renaud JR Director Grant (A) +17,096 opt — EDGAR
2026-06-11 Daniella Beckman Director Grant (A) +17,096 opt — EDGAR
2026-06-11 Erez Chimovits Director Grant (A) +17,096 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

UPB Insider Holdings

6 insiders · @ $2.88
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Erez Chimovits Director 973,716 $2.81M $14.03M 4 2026-06-11
2 Everett Rand Sutherland Chief Executive Officer 68,717 $198.2K -$43.7K 5 2026-09-17
3 Aaron Deykin Chief Medical Officer 32,302 $93.2K -$18.7K 5 2026-09-17
4 Michael Gray CFO and COO 27,942 $80.6K -$17.8K 5 2026-09-17
5 Adam Houghton Chief Business Officer 22,901 $66.1K -$14.6K 5 2026-09-17
6 Allison Ambrose General Counsel 15,563 $44.9K -$10.0K 6 2026-09-17
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

UPB Board & Officers

As of SEC filings through Sep 17, 2026

Directors 7

Officers 5

Changes in the last 10 years (29)
Jun 12, 2025Erez Chimovits no longer listed as a 10% owner in SEC filings
Dec 16, 2024Allison Ambrose became General Counsel
Oct 15, 2024Wellington Biomedical Innovation Master Investors (Cayman) II L.P. reported in an SEC filing no longer being a 10% owner
Oct 10, 2024Wellington Biomedical Innovation Master Investors (Cayman) II L.P. became a 10% owner
Oct 10, 2024Ronald C Renaud JR became a director
Oct 10, 2024Orbimed Advisors LLC became a director
Oct 10, 2024Orbimed Advisors LLC became a 10% owner
Oct 10, 2024OrbiMed Israel GP II, L.P. became a director
Oct 10, 2024OrbiMed Israel GP II, L.P. became a 10% owner
Oct 10, 2024OrbiMed Capital GP VIII LLC became a director
Oct 10, 2024OrbiMed Capital GP VIII LLC became a 10% owner
Oct 10, 2024OrbiMed Advisors Israel II Ltd became a director
Oct 10, 2024OrbiMed Advisors Israel II Ltd became a 10% owner
Oct 10, 2024Michael Gray became CFO and COO
Oct 10, 2024Marcella K. Ruddy became a director
Oct 10, 2024Liam Ratcliffe became a director
Oct 10, 2024Len Blavatnik became a 10% owner
Oct 10, 2024Harold Edward Fleming became a director
Oct 10, 2024Everett Rand Sutherland became a director
Oct 10, 2024Everett Rand Sutherland became Chief Executive Officer
Not reported recently (9)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
37 ETFs hold UPB
25 shown · $21.17M total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $7.6M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.00% $2.6M $75.1B 2026-10-20
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $2.5M — 2026-09-30
4 SCHA Schwab U.S. Small-Cap ETF Nport 0.01% $1.4M — 2026-05-31
5 VTWO Vanguard Russell 2000 ETF Vanguard 0.01% $1.2M — 2026-09-30
6 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.01% $1.0M $13.7B 2026-10-20
7 IBB iShares Biotechnology ETF iShares (BlackRock) 0.01% $784,259 $11.0B 2026-10-20
8 FFSM Fidelity Fundamental Small-Mid Cap ETF Nport 0.04% $591,323 — 2026-07-31
9 VHT Vanguard Health Care ETF Vanguard 0.00% $486,563 — 2026-09-30
10 SBIO ALPS Medical Breakthroughs ETF Nport 0.29% $465,644 — 2026-05-31
11 SURI Simplify Propel Opportunities ETF Nport 0.56% $429,822 — 2026-06-30
12 DFAS Dimensional US Small Cap ETF Dimensional 0.00% $420,363 — 2026-10-20
13 BBC Virtus Biotech Clinical Trials Etf Nport 0.69% $321,507 — 2026-07-31
14 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.01% $227,475 $3.1B 2026-10-20
15 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.01% $212,634 — 2026-07-31
16 DFMC Dimensional US Micro Cap ETF Dimensional 0.00% $207,411 — 2026-10-20
17 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.01% $187,333 — 2026-09-30
18 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.00% $177,141 $6.6B 2026-10-20
19 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $170,678 — 2026-05-31
20 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $141,257 $97.4B 2026-10-20
21 RSSL Global X Russell 2000 ETF Global X 0.00% $48,191 — 2026-10-21
22 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $40,453 — 2026-10-20
23 DXUV Dimensional US Vector Equity ETF Dimensional 0.00% $32,726 — 2026-10-20
24 IWV iShares Russell 3000 ETF iShares (BlackRock) 0.00% $27,436 $20.6B 2026-10-20
25 IBBQ Invesco Nasdaq Biotechnology ETF Nport 0.04% $23,742 — 2026-05-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-2.89
TTM Revenue
$3.16M
TTM Net Income
$-156.50M
TTM Op. Cash Flow
$-136.34M
Quarterly figures (7 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$773.00K$-39.70M$-0.73$-35.62M
Q1 '262026-03-31$1.03M$-40.59M$-0.75$-47.85M
Q4 '252025-12-31$668.00K$-42.46M$-0.78$-30.63M
Q3 '252025-09-30$683.00K$-33.75M$-0.63$-22.24M
Q2 '252025-06-30$937.00K$-39.97M$-0.74$-39.24M
Q1 '252025-03-31$566.00K$-27.27M$-0.51$-41.16M
Q4 '242024-12-31$613.00K$-21.79M$12.57$-19.61M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.58
P/S
49.46
EV/EBITDA
—
EV/Sales
24.32
ROE
-57.8%
ROA
-55.7%
Div Yield
0.00%
FCF Yield
-87.30%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$156.18M
as of 2026-10-22
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
4.51M
SI % of Float
13.29%
Days to Cover
7.68
Short Vol Ratio
25.2%
Free Float
33.97M
Float %
62.0%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14